Introduction 1
The hypothalamic neuropeptide oxytocin, besides its physiological function in parturition and 2 lactation, is primarily known for its role in psychosocial and affective processing, e.g., in 3 bonding behavior, emotion regulation, and sexual function [1] [2] [3] [4] . Oxytocin is released into 4 the circulation by axonal terminals in the posterior pituitary and, in addition, acts directly on 5 central nervous receptors. Interestingly, oxytocin is produced in hypothalamic regions that 6 also regulate appetite and metabolism and are targets of appetite-regulating hormones like 7 leptin, cholecystokinin (CCK) and ghrelin [5, 6] . Important insights into the role of oxytocin 8 in the central nervous regulation of metabolic functions have been obtained in animal 9
experiments (e.g., [7] [8] [9] ; for review see [10, 11] ) which indicate that oxytocin contributes to 10 the control of food intake, energy expenditure and glucose homeostasis [12, 13] . In recent 11 years, first experiments to investigate respective effects in the human organism have been 12 performed, primarily relying on the intranasal pathway of neuropeptide delivery to the brain. 13
Intranasal administration of oxytocin in humans has been repeatedly shown to inhibit eating 14 behavior driven by hunger due to energy depletion as well as by more reward-related, 15
'hedonic' factors associated with food intake [14] [15] [16] . This short review summarizes the 16 effects of oxytocin on ingestive behavior in healthy humans and subjects with obesity or 17 eating disorders, with the aim of providing an update on current research and future 18 directions, and looks at possible links between oxytocin's eating-related function and its role 19 in psychosocial regulation (see Figure 1 for an overview of oxytocin effects). 20 21
The neuropeptide oxytocin 22
Oxytocin is a nine-amino acid neuropeptide hormone that is predominantly produced in two 23 hypothalamic regions, the paraventricular nucleus (PVN) and the supraoptic nucleus [17] . 24 PVN oxytocin neurons project to the pituitary gland (about 40%) and a number of brain areas 25 including the brainstem. Around ten percent of PVN neurons project to three core areas of the 26 brainstem that play an important role in the regulation of food intake: nucleus tractus 27 solitarius, dorsal motor nucleus of the vagus nerve (DMNV), and area postrema [18, 19] . 28
Oxytocin in addition is active in brain areas of relevance for reward-and eating-related 29 behavior such as the ventral tegmental area (VTA), nucleus accumbens (NAcc), and nucleus 30 stria terminalis [20] . It is assumed that only a small ratio of oxytocin released into the 31 periphery via the posterior pituitary passes the blood-brain barrier to re-enter the brain [21] , 32 which might explain why oxytocin concentrations are up to 1000 times higher in the brain 33 than in the blood. In conjunction with the observation that the half-life of the peptide in the 34 central nervous system (CNS) is over three times longer than in the periphery (19 vs. 6 35 minutes) [22, 23] , this pattern furthermore points to the specific relevance of the hormone for 36 central nervous functions [24] . 37
The role of oxytocin in the periphery and in particular in the female reproductive 38 system is well established, first of all with regard to fertilization and parturition. During 39 pregnancy, the uterus increases its oxytocin sensitivity before giving birth, and receptor 40 density increases during labor [25] . The human ovary also expresses oxytocin receptors 41 (OXTR), and oxytocin possibly affects the fertilization process and the very early 42 development of the embryo [26] . The most prominent role of oxytocin in humans concerns 43 lactation. The infant triggers secretion of the peptide by sucking on the mother's nipple, 44 which stimulates additional milk ejection. The male reproductive system has also been 45 observed to be oxytocin-sensitive [27] . 46
The G-protein coupled OXTR [28] can be found in a wide range of brain regions (see 47 ref. [27, 29] for review), e.g., in hypothalamus, amygdala, anterior cingulate cortex, olfactory 48 nucleus, and in limbic areas [30] . Moreover, oxytocin interacts with other neurotransmitters 49 to influence brain function. It has been suggested that serotonin increases oxytocin 50 concentrations [31] and that dopamine interacts with oxytocin [32] to modulate activity of the 51 brain's reward circuitry [32, 33] (see also chapter 4.2 of this review). The latter interaction has 52 been assumed to be of relevance for behavioral disorders such as sexual dysfunction, autism, 53 depression, but also eating disorders (see ref. [34] for further reading). In addition to its 54 expression in the brain, oxytocin is expressed in myenteric and submucous ganglia and nerve 55 fibres of the human gastrointestinal tract [35] , with potential consequences for eating 56 behavior and metabolism. 57
A suitable way to study the contribution of (neuro)peptidergic messengers to human 58 brain function is the intranasal route of administration, which largely bypasses the blood-59 brain barrier (BBB) and delivers neuropeptides directly to the CNS. In humans, intranasally 60 administered peptides have been found to reach the CNS within 45 min after delivery [36] . 61
Since intra-neuronal transport of neuropeptides from the nasal mucosa to the olfactory bulb 62 normally takes several hours [37] , it is assumed that intranasally administered neuropeptides 63 travel to the CNS via extra-neuronal pathways, bypassing the BBB paracellularly by 64 diffusing into the subarachnoidal space across the olfactory epithelia and through intercellular 65 clefts between sustentacular cells and olfactory neurons [38] . Passage of intranasally 66 delivered peptides to the brain may also be established along cranial and trigeminal nerve 67 branches [39] . Most recently, bulk flow within the perivascular space of cerebral blood 68 vessels has been identified as another transport mechanism after intranasal administration 69 Recent experiments by Striepens and colleagues [44] suggest that plasma oxytocin 73 concentrations peak 15 min after intransal adminstration (24 IU) while cerebrospinal fluid 74 oxytocin concentrations reach their maximum up to 75 min post administration, so that the 75 strongest brain effect of intranasal oxytocin might emerge around 60 min after 76 administration. Intranasally administered oxytocin has been assumed to travel along the 77 olfactory system to amygdaloid nucei, which are directly connected to the hypothalamus. 78
This projection also influences the ventral striatum, an essential part of the reward system, 79 with potential modulatory effects on forebrain structures [20] Person variables moreover appear to play an important role in the interplay between oxytocin 120 and the regulation of anxiety and stress [74, 80] . 121
Oxytocin has also been implicated to contribute to memory function. In recent animal 122 studies, oxytocin was found to protect hippocampus plasticity against stress [81] and to 123 enhance the formation of hippocampus-dependent memory [82] . The hippocampal formation 124 is essential for the formation and storage of declarative memory, i.e., memory for facts and 125 events that can be consciously recollected [83] . Mice lacking oxytocin display impairments in 126 social memory function, failing to recognize animals they have been familiarized with [84] . 
Oxytocin's impact on eating behavior and energy homeostasis in animals 156
Thanks to research efforts in the past two to three decades, the contribution of oxytocin to the 157 regulation of eating behavior and metabolism has gained increasing attention, and it seems 158 like oxytocin is now not only recognized as a social peptide, but also as a messenger with 159 relevance for food intake control. First hints at a role of oxytocin in the regulation of food Further experiments indicated that ICV administration of oxytocin reduces food intake in 165 normal-weight rats [7] . Importantly, animals with genetically or diet-induced obesity (DIO) 166 also respond to oxytocin administration. Thus, IP and subcutaneous (SC) injection of 167 oxytocin suppresses food intake and SC injection reduces fat mass in DIO mice [8] , and also 168 improves insulin sensitivity [103] . In ob/ob mice, two weeks of SC oxytocin administration 169 led to a reduction in food intake and body weight [ indicates that long-term third ventricular oxytocin infusion also affects fat consumption and 192 fat oxidation: in rats kept on a high-fat diet, oxytocin curbed calorie consumption and 193 decreased body weight gain relative to controls, effects that were not observed when the rats 194 were on a chow-diet. Importantly, oxytocin also reduced energy intake and prevented weight 195 gain in animals on a sucrose-free high-fat diet. In sum, these experiments indicated that 196 oxytocin maintains energy expenditure despite concurrent weight loss, increases fat oxidation 197 and may boost CCK-mediated satiety responses [11] . The ability of oxytocin to sensitize 198 satiety centers in the hindbrain to the effects of CCK can be assumed to play a role in this 199
context [6] . The first study addressing the impact of intranasal oxytocin on food intake investigated if the 222 peptide reduces hunger-and reward-driven food intake in normal-weight healthy men [14] . It 223 turned out that oxytocin strongly decreased the consumption of chocolate cookies assessed 224 around three hours after peptide administration and 90 min after ad-libitum breakfast intake, 225
i.e., at a time-point when reward-related eating motivation prevailed. In contrast, hunger-226 driven breakfast intake in the fasted state was not affected by oxytocin [14] . In that study, in 227 accordance with experiments in humans [79] and animals [12, 108] 
normal-weight and obese subjects [16] , cookie intake turned out to be likewise reduced by 236 oxytocin and the peptide induced comparable changes in stress hormone-and glucose 237 homeostasis-related blood parameters in obese participants. Remarkably, obese individuals in 238 addition decreased hunger-driven breakfast intake after oxytocin administration, i.e., 239 displayed a hypophagic effect that was absent in normal-weight humans. However, oxytocin-240 induced reductions in hunger-driven food intake from a breakfast buffet were found in obese, 241 but also normal-weight participants in related studies [15] , which moreover indicated that the 242 anorexigenic effect centered on fat intake (before correction for multiple comparisons). These 243 results were accompanied by an oxytocin-induced increase in circulating CCK concentrations 244 that, as the authors report, were not related to changes in calorie intake, and signs of 245 improved insulin sensitivity after administration of the peptide. response to cues that signal social reward or punishment, although this effect is modulated by 252 intraindividual differences in sociability [129] . Moreover, variability in the oxytocin gene 253 explains interindividual differences in dopaminergic responses to stress measured by positron 254 emission tomography [130] . These findings support the tentative assumption that oxytocin 255 exerts some of its effects on food intake in humans by acting on reward processing, although 256 at the moment it remains to be seen if the effect of oxytocin on eating behavior is primarily 257 hunger-or reward-driven. 258
There is some first evidence that in addition to acting via homeostatic and reward-259 related mechanisms, oxytocin also reduces food intake by enhancing cognitive control 260 mechanisms. Thus, a recent neuroimaging study [131] revealed that oxytocin reduces craving 261 for food and in parallel increases activity of prefrontal cortical areas in women. Clearly, 262 further studies are needed to pinpoint the exact mechanisms behind the hypophagic effect of 263 oxytocin in humans. They should also answer the obvious question whether this effect is 264 conveyed, at least in part, via oxytocin's contribution to the regulation of psychosocial 265 functions, so that a strong modulatory role of social context in the extent or even direction of 266 oxytocin's effect on eating behavior would be expected (see chapter 5). 267
Oxytocin as a potential intervention in eating disorders and obesity 268
The contribution of oxytocin to the control of food intake as illustrated in studies in animals 269 and healthy subjects raises the question if oxytocin might support therapeutic interventions 270 aimed at specific eating disorders. Individuals with anorexia nervosa have been found to 271 display increased oxytocin concentrations after standardized meal intake [132] , suggesting 272 that changes in oxytocin signaling might be a feature of or even a pathophysiological factor 273 in this disorder. Accordingly, anorexia has been associated with epigenetic dysregulation of 274 the OXTR gene [133] . Intranasal oxytocin administration to patients with anorexia nervosa 275 changes their attitude towards social and food-related stimuli; the peptide induces a shift from 276 the avoidance of angry faces towards increased vigilance and moreover attenuated attention 277 to food stimuli [134, 135] . These and related promising findings [136, 137] by the group of 278 Janet Treasure suggest that therapeutic approaches aiming at improving emotional and 279 eating-related processes in anorectic, and moreover bulimic patients might be supported by 280 concurrent oxytocin delivery [138] , but will need to be corroborated in larger clinical trials. 281
Of note, irregularities in oxytocin signaling, i.e., an OXTR gene polymorphism, have also 282 been associated with bulimia nervosa [139] . In animal experiments, DIO rhesus monkeys receiving subcutaneous oxytocin for four 307 weeks reduced their food intake by around 27% and their body weight by 3.3%, while their 308 energy expenditure increased by 14% [9] . Obese human subjects reduced their food intake by 309 around 10% in the first hours after acute intranasal administration [16] . When obese 310 individuals received four daily intranasal doses of 24 IU oxytocin for a duration of eight 311 weeks, they were observed to lose around 9 kg of body weight and to show a decrease in 312 waist and hip circumference [103] . Since the interpretation of these results is complicated by 313 the large pre-administration differences in BMI and age between the treatment and the 314 control groups (36 vs. 30 kg/m 2 , 29 vs. 41 years), further and possibly larger trials are clearly 315 needed to sound the potential of oxytocin as an anti-obesity drug. In these studies it will be of 316 high relevance to address potential sex differences, which are suggested by some experiments 317 in animals [13] , and carefully control for side effects on metabolic parameters but also 318 
